Tiziana Life Sciences Ltd
TLSA
$0.8092
-$0.0508-5.91%
Weiss Ratings | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D- | |||
Reward Grade | E | |||
Rating Factors | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Fair | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -0.19 | |||
Price History | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -23.66% | |||
30-Day Total Return | -28.39% | |||
60-Day Total Return | 11.61% | |||
90-Day Total Return | -12.04% | |||
Year to Date Total Return | 18.86% | |||
1-Year Total Return | 86.02% | |||
2-Year Total Return | -19.88% | |||
3-Year Total Return | -17.43% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -54.97% | |||
52-Week Low % Change | 109.76% | |||
Price | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $1.91 | |||
52-Week Low Price | $0.41 | |||
52-Week Low Price (Date) | Apr 15, 2024 | |||
52-Week High Price (Date) | Mar 07, 2025 | |||
Valuation | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 93.81M | |||
Enterprise Value | 92.86M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.13 | |||
Earnings Per Share Growth | -28.86% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | -- | |||
Price/Book (Q) | 47.51 | |||
Enterprise Value/Revenue (TTM) | -- | |||
Price | $0.81 | |||
Enterprise Value/EBITDA (TTM) | -5.88 | |||
Enterprise Value/EBIT | -5.88 | |||
Market Cap Category | Micro Cap | |||
Dividends and Shares | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 103.10M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | -- | |||
Address | -- | |||
Website | www.tizianalifesciences.com | |||
Country | United Kingdom | |||
Year Founded | 1998 | |||
Profitability | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -- | |||
Profit Margin | -- | |||
Management Effectiveness | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -69.58% | |||
Return on Equity | -- | |||
Income Statement | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | -- | |||
Total Revenue (TTM) | -- | |||
Revenue Per Share | -- | |||
Gross Profit (TTM) | -- | |||
EBITDA (TTM) | -15.79M | |||
EBIT (TTM) | -15.80M | |||
Net Income (TTM) | -13.73M | |||
Net Income Avl. to Common (TTM) | -13.73M | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | 45.99% | |||
EPS Diluted (TTM) | -0.13 | |||
EPS Diluted Growth (Q YOY) | 46.32% | |||
Balance Sheet | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 1.13M | |||
Cash Per Share (Q) | $0.01 | |||
Total Current Assets (Q) | 7.75M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 1.86M | |||
Current Ratio (Q) | 0.854 | |||
Book Value Per Share (Q) | $0.02 | |||
Total Assets (Q) | 10.96M | |||
Total Current Liabilities (Q) | 9.07M | |||
Total Debt (Q) | 179.00K | |||
Total Liabilities (Q) | 9.11M | |||
Total Common Equity (Q) | 1.86M | |||
Cash Flow | TLSA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -1.01M | |||
Cash from Financing (TTM) | 9.00K | |||
Net Change in Cash (TTM) | -5.47M | |||
Levered Free Cash Flow (TTM) | -199.40K | |||
Cash from Operations (TTM) | -3.91M | |||